Extreme Networks' impressive EPS growth and significant insider ownership indicate strong confidence in future performance. However, investors should also consider its industry price-to-earnings ratio comparison.
Despite the recent drop in share price, long-term investors may still see a 10% annual return over five years. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering.
Despite Extreme Networks' high P/E ratio and low forecast growth, investors hope for a business turnaround. However, analysts lack confidence in this, suggesting potential risk for shareholders and overpayment danger for new investors.
Analysts opine that despite Extreme Networks' good management, the Enterprise Networking market needs more AI-based workflow automation. They also note waning demand and inventory issues. They suggest resetting Extreme's revenue expectations to about $1.1B.
The surge in insider selling at Extreme Networks signals a possible lack of faith in the firm's future, raising potential red flags among shareholders.
The notable EPS growth and insider investment hint at Extreme Networks' positive future. Continuous margin and revenue increases boost favorable views on the company's potential. A promising investment, however, potential investors should review its price-to-earnings ratio and watch for further insider transactions.
Analysts express reservations about stock due to weakened guidance, macro uncertainty. Predict stock pressure until revenue growth restarts, potential bounce on Investor Day. Company's long-term status, universal hardware/cloud platform, could influence future performance, but lowered outlook might double-impact short term earnings.
Gainers: •$Rocket Pharmaceuticals (RCKT.US)$+10.5% (Presents Positive Top-line Data from Severe Leukocyte Adhesion Deficiency-I Program at the 25th Annual Meeting of the American Society of Gene and Cell Therapy) •$Canada Goose (GOOS.US)$+9.4% (the company reported an unexpected profit as well as better-than-expected revenue) •$SIGA Technologies (SIGA.US)$+6.4% (FDA approves Intravenous (IV) Formulation of TPOXX (tecovirimat) for t...
Extreme Networks Stock Forum
• $Rocket Pharmaceuticals (RCKT.US)$ +10.5% (Presents Positive Top-line Data from Severe Leukocyte Adhesion Deficiency-I Program at the 25th Annual Meeting of the American Society of Gene and Cell Therapy)
• $Canada Goose (GOOS.US)$ +9.4% (the company reported an unexpected profit as well as better-than-expected revenue)
• $SIGA Technologies (SIGA.US)$ +6.4% (FDA approves Intravenous (IV) Formulation of TPOXX (tecovirimat) for t...
• $National CineMedia (NCMI.US)$ +17.9% (AMC discloses 6.8% stake in NCMI)
• $MagnaChip Semiconductor (MX.US)$ +14.8% (report that private equity firms including Carlyle Group (CG) will bid for the company)
• $DLocal (DLO.US)$ +13.7% (In reaction to earnings)
• $SiriusPoint (SPNT.US)$ +8.2% (Chairman and CEO resigns to pursue other opportunities)
• $Beyond Air (XAIR.US)$ +6.4% (presents positive study update from the at-home LungF...
No comment yet